The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | SHORESPAN-017 extension data support the long-term safety of bomedemstat in MF and ET
Francesca Palandri, MD, PhD, University of Bologna, Bologna, Italy, discusses findings from the Phase III SHORESPAN-017 extension study (NCT06351631) evaluating bomedemstat in patients with myelofibrosis (MF) and essential thrombocythemia (ET). She reviews the favorable safety profile observed in the extension study, highlighting manageable gastrointestinal adverse events and dysgeusia, and considers how bomedemstat may fit into the evolving treatment landscape.This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Well, the SHORESPAN-017 study was a very important cumulative study, collecting data from MF and ET patients with Mubritinib. And the aim of the study was to evaluate the safety of this compound in this broad population. And we could study, in a prospective way 56 patients and look at which were the main toxicities related to the study drug. What really emerged is that Mubritinib is a quite secure drug...
Well, the SHORESPAN-017 study was a very important cumulative study, collecting data from MF and ET patients with Mubritinib. And the aim of the study was to evaluate the safety of this compound in this broad population. And we could study, in a prospective way 56 patients and look at which were the main toxicities related to the study drug. What really emerged is that Mubritinib is a quite secure drug. It is a safe drug with GI toxicity as the predominantly expressed side effects. And also some patients reported some dysgeusia. Both toxicities were generally very manageable with dose modifications or temporary discontinuations and do not really provide the reasons for discontinuation of the treatment. So overall the safety profile resulted to be very good in this observational prospective study.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
